https://scholars.lib.ntu.edu.tw/handle/123456789/528707
標題: | Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region | 作者: | PO-REN HSUEH Graybill J.R. Playford E.G. Watcharananan S.P. Oh M.-D. Ja'alam K. Huang S. Nangia V. Kurup A. Padiglione A.A. |
公開日期: | 2009 | 卷: | 34 | 期: | 3 | 起(迄)頁: | 205-209 | 來源出版物: | International Journal of Antimicrobial Agents | 摘要: | Invasive candidiasis has emerged as an important nosocomial infection, especially in critically ill patients. The incidence of candidaemia in Intensive Care Units (ICUs) is 5- to 10-fold higher than in the entire hospital and the crude mortality rate of patients with candidaemia is between 35% and 60%. Candida albicans remains the predominant cause of invasive candidiasis in ICUs, followed by Candida tropicalis, Candida glabrata and Candida parapsilosis. Invasive isolates of Candida spp. remain highly susceptible to fluconazole (>90% susceptible), although among Asia-Pacific countries the susceptibility rate of C. glabrata to fluconazole varies widely from 22% to 72%. Early diagnosis and prompt initiation of antifungal therapy are crucial for the effective treatment of invasive candidiasis. However, invasive candidiasis is difficult to diagnose owing to its non-specific clinical features, and delayed therapy is a major contributor to poor outcomes. Combining clinical risk factors with Candida colonisation parameters appears promising for guiding early interventions. Because of considerable regional variability, local epidemiological knowledge is critical in the effective management of invasive candidiasis among ICU patients in Asia-Pacific. ? 2009 Elsevier B.V. and the International Society of Chemotherapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/528707 | ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2009.03.014 | SDG/關鍵字: | amphotericin B; amphotericin B lipid complex; anidulafungin; antibiotic agent; caspofungin; echinocandin; fluconazole; micafungin; placebo; triazole; voriconazole; antifungal susceptibility; article; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropicalis; clinical feature; clinical trial; consensus development; drug efficacy; early diagnosis; early intervention; fungal colonization; fungus isolation; geographic distribution; hospital infection; human; incidence; infection control; intensive care unit; invasive candidiasis; mortality; outcome assessment; postoperative infection; preoperative treatment; prevalence; priority journal; risk factor; therapy delay; treatment duration |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。